Abstract:RATIONALE & OBJECTIVE: <AbstractText Label="RATIONALE & OBJECTIVE">Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) with circulating serum autoantibodies to PLA2R (SAb+) but no deposits of PLA2R antigen in glomerular tissue by immunofluorescence (GAg-) has been reported. However, little is known about the clinicopathological characteristics or prognosis of this subtype of MN.</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN">Retrospective cohort study.</AbstractText>SETTING & PARTICIPANTS: <AbstractText Label="SETTING & PARTICIPANTS">130 SAb+ patients in China with biopsy-proven MN who had follow-up data and received immunosuppressive therapy. The median follow-up was 16 (IQR, 9-25) months.</AbstractText>PREDICTOR: <AbstractText Label="PREDICTOR">PLA2R antigen detection by immunofluorescence staining of kidney biopsy specimens.</AbstractText>OUTCOMES: <AbstractText Label="OUTCOMES">Complete remission (CR) was defined as proteinuria levels <0.3 g/d and a >50% decrease compared with a previously established baseline. Partial remission (PR) was defined as proteinuria levels <3.5 g/d and a >50% decrease compared with a previously established baseline. The kidney function outcome was defined as a >40% decrease in estimated glomerular filtration rate (eGFR) at the end of the study compared with baseline.</AbstractText>ANALYTICAL APPROACH: <AbstractText Label="ANALYTICAL APPROACH">Kaplan-Meier analysis of PR and CR comparing SAb+/GAg+ and SAb+/GAg- patients. Cox proportional hazards models to examine these associations were adjusted for confounders.</AbstractText>RESULTS: <AbstractText Label="RESULTS">Among 130 SAb+ patients with PLA2R-associated MN, 18 were GAg-. Compared with SAb+/GAg+ patients, those who were SAb+/GAg- presented with more severe kidney injury as evidenced by higher SAb titer, greater proteinuria, lower serum albumin concentrations, lower eGFR (all P < 0.05), and more severe disease with higher chronicity scores (P < 0.001) on kidney biopsies. SAb+/GAg- patients exhibited a significantly lower probability of PR (P < 0.001) and CR (P = 0.03) and were more likely to experience a >40% decrease in eGFR (P = 0.008) than patients who were SAb+/GAg+. After adjusting for clinical and pathologic variables available at the time of biopsy, compared with SAb+/GAg+ patients, SAb+/GAg- patients had a lower rate of experiencing remission (hazard ratio, 0.32 [95% CI, 0.15-0.68]; P = 0.003) and a higher rate of the >40% eGFR decrease outcome (hazard ratio, 7.66 [95% CI, 1.54-38.08]; P = 0.01).</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS">Retrospective study, small sample size, and lack of a uniform approach to treatment.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Seropositive PLA2R-associated MN without PLA2R staining on kidney biopsy may represent a distinct clinical subtype with more severe disease and a worse prognosis. GAg- is independently associated with poor response to treatment and >40% eGFR decrease in seropositive PLA2R-associated MN.</AbstractText>

Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies

Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody.

Quantitative Detection of Anti-Pla2r Antibodies Targeting Different Epitopes and Its Clinical Application in Primary Membranous Nephropathy.

Peer Review #1 of "retrospective Study: Clinicopathological Features and Prognosis of Idiopathic Membranous Nephropathy with Seronegative Anti-Phospholipase A2 Receptor Antibody (V0.2)"

Serum Phospholipase A2 Receptor Antibodies and Immunoglobulin G Subtypes in Adult Idiopathic Membranous Nephropathy: Clinical Value Assessment.

Urine PLA2R Antibody Detection in Hazard Stratification of PLA2R-Associated Membranous Nephropathy.

Clinical Features and Pathology of PLA2R and THSD7A-Associated Membranous Nephropathy: A Single-Center Study from China

The Application of Podocyte Antigen PLA2R and Anti-Pla2r Antibody in the Diagnosis and Treatment of Membranous Nephropathy

The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy

A Novel Time-Resolved Fluoroimmunoassay Based on Magnetic Microspheres Method for Detecting Antibodies Against the Phospholipase A2 Receptor.

Detection And Clinical Significance Of Glomerular M-Type Phospholipase A(2) Receptor In Patients With Idiopathic Membranous Nephropathy

Clinicopathological Characteristics and Outcomes of PLA2R-Associated Membranous Nephropathy in Seropositive Patients Without PLA2R Staining on Kidney Biopsy

Clinicopathological Features of Idiopathic Membranous Nephropathy Combined with Iga Nephropathy: A Retrospective Analysis of 9 Cases

Serum Anti-Pla2r Antibody And Glomerular Pla2r Deposition In Chinese Patients With Membranous Nephropathy

Clinicopathological and prognostic characteristics of idiopathic membranous nephropathy with dual antigen positivity

Association of Serum Mannose-Binding Lectin, Anti-Phospholipase A2 Receptor Antibody and Renal Outcomes in Idiopathic Membranous Nephropathy and Atypical Membranous Nephropathy: a Single Center Retrospective Cohort Study.

Anti-PLA2R autoantibodies in serum and IgG subclass deposits on glomeruli in undetermined atypical membranous nephropathy

Progress on the M-type Phospholipase A2 Receptor in Idiopathic Membranous Nephropathy

Research progress of idiopathic membranous nephropathy associated antigen phospholipase A2 receptor and thrombospondin type-1 domain containing 7A

Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy.

Clinicopathological features and outcomes of PLA2R-related membranous nephropathy with renal glycosuria